EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting nerve growth factor: an Achilles’ heel for tumors?

Elizabeth Repasky, Hemn Mohammadpour

Journal for ImmunoTherapy of Cancer · 2025-05 · 13 (5) · e011609

DOI: 10.1136/jitc-2025-011609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 02.05.2025. Verfasst von Elizabeth Repasky und 1 weiteren Autor:innen. Beteiligte Einrichtung: Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA elizabeth.repasky@RoswellPark.org Hemn.Mohammadpour@RoswellPark.org. Hauptthemen laut MEDLINE: Neoplasms, Nerve Growth Factor. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A tumor’s ability to attract innervation is a critical factor in tumor progression and immune escape, with the sympathetic nervous system playing a major role. Catecholamines released by sympathetic nerves activate adrenergic receptors on tumor cells, enhancing growth and resistance to therapies, while activation of adrenergic receptors on immune cells triggers immunosuppressive activity in the tumor microenvironment. Nerve growth factor (NGF) produced by tumor cells is a key driver of tumor innervation, making it a promising target for novel therapeutic strategies. In this commentary, we highlight a recent study by Yang et al , which examines NGF single-chain variable fragment (scFv)-secreting chimeric antigen receptor(CAR) T cells and the impact of NGF neutralization by CAR T cells on CAR T-cell function and the remodeling of the tumor microenvironment. This work shows that we may be able to exploit a tumor-derived survival factor as a vulnerability and a means to enhance antitumor immune activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsNerve Growth FactorHumansTumor MicroenvironmentAnimals

Stichwörter der Autor:innen

Chimeric antigen receptor - CARImmunosuppressionTumor microenvironment - TME

Substanzen

Nerve Growth Factor

Autor:innen und Institutionen

  • Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA elizabeth.repasky@RoswellPark.org Hemn.Mohammadpour@RoswellPark.org.
  • Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA elizabeth.repasky@RoswellPark.org Hemn.Mohammadpour@RoswellPark.org.

Förderung

  • NHLBI NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • V Foundation for Cancer Research
  • National Heart, Lung, and Blood Institute
  • DOD Peer Reviewed Cancer Research Program

Zitieren

APA

Repasky, E., & Mohammadpour, H. (2025). Targeting nerve growth factor: an Achilles’ heel for tumors?. Journal for ImmunoTherapy of Cancer, 13(5), e011609. https://doi.org/10.1136/jitc-2025-011609

Vancouver

Repasky E, Mohammadpour H. Targeting nerve growth factor: an Achilles’ heel for tumors?. Journal for ImmunoTherapy of Cancer. 2025;13(5):e011609. doi:10.1136/jitc-2025-011609

BibTeX
@article{Repasky2025,
  author = {Repasky, Elizabeth and Mohammadpour, Hemn},
  title = {Targeting nerve growth factor: an Achilles’ heel for tumors?},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {5},
  pages = {e011609},
  doi = {10.1136/jitc-2025-011609}
}
Kostenlos starten →